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Abstract
Galectin-3 is a lectin involved in fibrosis, inflammation and proliferation. Increased circulating levels of galectin-3 have been
associated with various diseases, including cancer, immunological disorders, and cardiovascular disease. To enhance our
knowledge on galectin-3 biology we performed the first genome-wide association study (GWAS) using the Illumina
HumanCytoSNP-12 array imputed with the HapMap 2 CEU panel on plasma galectin-3 levels in 3,776 subjects and follow-up
genotyping in an additional 3,516 subjects. We identified 2 genome wide significant loci associated with plasma galectin-3
levels. One locus harbours the LGALS3 gene (rs2274273; P = 2.356102188) and the other locus the ABO gene (rs644234;
P = 3.65610247). The variance explained by the LGALS3 locus was 25.6% and by the ABO locus 3.8% and jointly they
explained 29.2%. Rs2274273 lies in high linkage disequilibrium with two non-synonymous SNPs (rs4644; r2 = 1.0, and rs4652;
r2 = 0.91) and wet lab follow-up genotyping revealed that both are strongly associated with galectin-3 levels (rs4644;
P = 4.976102465 and rs4652 P= 1.506102421) and were also associated with LGALS3 gene-expression. The origins of our
associations should be further validated by means of functional experiments.
Citation: de Boer RA, Verweij N, van Veldhuisen DJ, Westra H-J, Bakker SJL, et al. (2012) A Genome-Wide Association Study of Circulating Galectin-3. PLoS
ONE 7(10): e47385. doi:10.1371/journal.pone.0047385
Editor: Yong-Gang Yao, Kunming Institute of Zoology, Chinese Academy of Sciences, China
Received July 9, 2012; Accepted September 12, 2012; Published October 9, 2012
Copyright:  2012 de Boer et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: PREVEND genetics is supported by the Dutch Kidney Foundation (Grant E033), the National Institutes of Health (grant LM010098), The Netherlands
organisation for health research and development (NWO VENI grant 916.761.70 & ZonMw grant 90.700.441), and the Dutch Inter University Cardiology Institute
Netherlands (ICIN). R.A. de Boer is supported by the Netherlands Heart Foundation (grant 2007T046) and the Innovational Research Incentives Scheme program of
the Netherlands Organization for Scientific Research (NWO VENI grant 916.10.117). BG Medicine Inc. provided an unrestricted research grant to the Department of
Cardiology of the University Medical Centre Groningen. N. Verweij is supported by the Netherlands Heart Foundation (grant NHS2010B280). I. Mateo Leach is
supported by the Netherlands Heart Foundation (grant NHS2008B065) The funders had no role in study design, data collection and analysis, decision to publish,
or preparation of the manuscript.
Competing Interests: We have read the journal’s policy and have the following potential conflicts of interest: BG Medicine, Inc., has certain rights related to
galectin-3 measurements. BG Medicine Inc. provided an unrestricted research grant to the Department of Cardiology of the University Medical Centre Groningen.
Drs. R.A. de Boer and D.J. van Veldhuisen have received consulting and speaker’s fees from BG Medicine, Inc.
* E-mail: p.van.der.harst@umcg.nl
. These authors contributed equally to this work.
Introduction
Galectin-3 (LGALS3) is a lectin and member of the galectin
family of carbohydrate binding proteins that have an affinity for
beta-galactosides. Galectin-3 plays a role in fibrosis, inflammation,
and proliferation [1,2,3]. Galectin-3 is secreted into the systemic
circulation by unknown mechanisms and is increasingly recog-
nised as a potential biomarker with clinical value. Increased
galectin-3 levels have been associated with various diseases,
including cancer [4,5], immunological disorders [6,7], and
cardiovascular traits [8,9]. Plasma galectin-3 levels are even being
considered as a marker of response to cancer treatment [10].
To enhance our knowledge on galectin-3 biology we performed
the first genome-wide association study (GWAS) on circulating
galectin-3 levels and observed two loci associated with circulating
galectin-3 levels. One locus harbours LGALS3 the gene encoding
galectin-3 and the other locus harbours the ABO gene which has
previously been associated with inflammatory markers, lipids and
haematological parameters.
Results
We performed a GWAS analysis of 2,269,099 genotyped or
imputed autosomal SNPs (HapMap 2 build 36 CEU panel) in
3,776 subjects of the PREVEND cohort (Table 1, Table S1). All
included subjects were of European descent. The quantile-quantile
plot for association is shown in Figure 1. There were 2 loci
significantly associated with galectin-3 levels (P,561028) and 11
SNPs showing suggestive evidence (P,561026 and P.561028,
Figure 2, Table 2). We performed further testing of the lead-
SNP of the loci using an additional subset of 3,516 independent
subjects derived from the PREVEND cohort (Table 1). Using
inverse-variance fixed effect meta-analysis we combined the
evidence. None of the suggestive, but both 2 P,561028 loci of
the discovery phase, were confirmed in the independent samples
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(Table 2). One locus harbours the LGALS3 gene and the other
locus harbours the ABO gene (Figure 3). The LGALS3 locus
accounted for 25.6% of the phenotypic variance. The ABO locus
explained 3.8% and together LGALS3 and ABO explained 29.2%
of the phenotypic variance. Of note, common genetic variation
explained twice the amount of the variation of circulating galectin-
3 levels compared to age, age squared (age2), gender, and body
mass index combined (11.6%).
Putative causal genetic variants
The lead SNP (rs2274273) of the LGALS3 locus lies in high LD
with two non-synonymous variants (rs4644; r2 = 1.0 and rs4652;
r2 = 0.91). As these variants were not present on our platform and
not well imputed we wet-lab genotyped these variants and
confirmed their association (Table 2). We next considered
potential confounding by the specific galectin-3 assay used and
noticed the epitopes of the antibodies used are directed against the
region harbouring the non-synonymous variant (Figure 4).
Therefore, this variant might affect the affinity of the antibody
and not represent a true difference in circulating galectin-3 levels.
We did not find variants in high LD (r2.0.8) associated with the
lead SNP (rs644234) of the ABO locus. Next, we searched for
eQTLs in 1,469 samples from peripheral blood for which gene
expression levels were obtained using illumine HT12V3 and
illumine H8v2 platforms [11]. rs2274273, rs4644, and rs4652 were
all associated with LGALS3 gene expression levels (Table 3) and
rs2274273 and rs4644 were also the strongest SNP associated with
that particular LGALS3 probe. Finally, to gain further insights we
queried the catalogue of published genome wide association
studies [12] for our loci and observed no previous associations for
the LGALS3 locus but many previous genome wide associations
findings have been reported for the ABO locus. Previous SNP
associations in or near ABO are in high linkage disequilibrium with
our lead SNP and include associations with inflammatory markers,
lipids and haematological parameters as well as diseases such as
cancer and coronary heart disease (Table S2).
Relevance of LGALS3 variant for prognostic value of
plasma galectin-3 levels
To study the relevance of the rs2274273 and rs4644 (r2 = 1)
variant in the LGALS3 locus for the prognostic value of the
galectin-3 assay on mortality in the general population we
repeated our earlier reported analyses [13] with and without
rs2274273 as a covariate in the model. Knowledge of the genotype
did not appear to change the prognostic value of plasma galectin-3
levels (Table 4).
Discussion
We report the first genetic association study on galectin-3
levels and identified 2 genome-wide significant loci; one including
the galectin-3 encoding gene (LGALS3) and the other gene being
ABO.
Galectin-3 is a member of the galectin family that comprises of
lectins with affinity for beta-galactosidases containing carbohy-
drates. The galectin gene family is evolutionarily ancient and can
be found in vertebrates, invertebrates, and even in protists
suggesting an important role in biology [14]. All galectins have a
carbohydrate-recognition domain (CRD) consisting of many
conserved sequence elements and each galectin has an individual
carbohydrate-binding preference [15]. Galectin-3 is an unique
galectin as it contains a non-lectin N-terminal region which is
connected to the CRD. Galectin-3 is therefore referred to as a
chimera-like galectin [1]. Galectin-3 does not contain a signal
sequence and is primarily localised within the cytoplasm. It can be
externalized by a mechanism independent of the endoplasmic
reticulum (ER)-Golgi complex [16,17]. Galectin-3 has high affinity
for lactose and N-acetyllactosamine but can also interact with a
wide array of other carbohydrates, membrane and extracellular
matrix proteins [18]. Upon ligand binding, galectin-3 (and its
ligands) forms cross-links, is involved in strengthening cell-cell
interactions, and is associated with stiffening of the extracellular
matrix and fibrogenesis. Galectin-3 has been shown to play a role
in inflammatory diseases, cancer and heart failure [3,15,19,20].
Little is known about the regulation of galectin-3. The galectin-3
promoter contains several responsive elements, including Sp-1,
AP-1 and cAMP responsive elements [21].
We now report the first 2 genome wide associations with
circulating galectin-3 levels. The strongest locus is within the
LGALS3 gene. The lead SNP (rs2274273) is in full LD with two
non-synonymous SNPs (rs4644 and rs4652) which were con-
firmed by follow-up genotyping. Both rs2274273 and rs4644
affected LGALS3 gene-expression providing a potential explana-
tion for the observed effect. In the current study we also tested
whether knowledge of the lead variant in the LGALS3 gene might
obscure the association of plasma galectin-3 levels with outcome
but it did not alter our previously published associations further
supporting a true effect of these variant on galectin-3 [13].
However, some note of caution is warranted. Associations of
coding SNPs (e.g. rs4644 and rs4652) that structurally change the
properties of its encoded protein can give rise to false positive
associations when that protein is also the phenotype under
investigation. The non-synonymous SNPs identified in our study
also lies within or near the epitopes of the antibodies used for the
galectin-3 assay (Figure 4). These antibodies might have
different affinities for the amino acid change and therefore this
association could also be artifactual. Interference of antibody
based assays with epitopes directed against regions harbouring
non-synonymous variants are not novel and have previously been
reported for the NPPA-NPPB locus when ANP levels were
measured [22]. Although gene-expression analyses and associa-
Figure 1. Quantile-quantile plots of observed versus expected
p-values for Galectin-3 with and without the GALS3 locus.
doi:10.1371/journal.pone.0047385.g001
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tion with outcome are suggesting a true effect, additional work
will be required to define the precise mechanisms of our reported
association at the LGALS3 locus.
Our second genome wide locus is the ABO locus. The ABO locus
is becoming an increasingly complex and pleiotropic locus.
Variants in ABO, and in high LD with our lead SNP (rs644234),
have been associated by genome wide association studies with
various blood measured traits and diseases. This includes several
inflammatory markers, lipids, hematological parameters, cancer,
inflammatory diseases, and cardiovascular diseases (Table S2).
Interestingly, galectin-3 levels also are associated with many of
these conditions. Galectin-3 can indeed bind to polysaccharides of
the ABO epitopes and even more strongly to the A- or B-histo-
blood group epitopes versus the O group [23]. However, this does
not explain how the ABO gene variant affects circulating galectin-3
levels.
In summary, we performed a GWAS on plasma galectin-3 levels
and identified two genome wide significant loci, one including the
LGALS3 gene and the other the ABO gene. The origins of these
associations should be further validated by means of functional
experiments.
Figure 2. Manhattan plot showing the association of SNPs with circulating galectin-3 levels in a GWAS of 3,776 individuals. The red
dotted line marks the threshold for genome-wide significance (P = 561028). Two loci reached genome-wide significance.
doi:10.1371/journal.pone.0047385.g002
Figure 3. Regional plots at the two significantly associated loci. Horizontal axis indicates chromosomal location and P-values are indicated in
the left y-axis. Each plot shows approximately 6 500 kb around each lead SNP and has known gene transcripts annotated at the bottom. The SNPs
are colored according to their degree of linkage disequilibrium (r2) with the lead SNP which is highlighted with a purple diamond and displayed by rs
number and significance level achieved in the discovery analysis.
doi:10.1371/journal.pone.0047385.g003
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Materials and Methods
Study population
We studied subjects included in the PREVEND cohort. The
PREVEND cohort has been described in detail elsewhere
[13,24,25]. In brief, 8,592 subjects were enrolled in the
PREVEND cohort in 1997–1998. Subjects were asked to refrain
from eating and drinking prior to their visit (fasting) in the
outpatient clinic (between 8:00 a. um and 1:00 pm) and blood
samples were drawn and stored at 280C. The PREVEND study
was approved by the local medical Ethical Committee, and is
conducted in accordance with the guidelines of the Declaration of
Helsinki. All subjects provided written informed consent.
Galectin-3 Measurements
For 7,968 subjects plasma was available to measure plasma
galectin-3 levels [13]. The galectin-3 assay is an enzyme-linked
Table 1. Galectin-3 levels in the PREVEND cohort, indicated




Galectin-3, median [IQR] 10.9 [9–13] 10.8 [9–13] 10.9 [9–13]
Galectin-3 (ng/ml), min-max 3.4–233 3.5–233 3.4–200
IQR; inter quartile range.
doi:10.1371/journal.pone.0047385.t001
Table 2. Discovery and follow-up genotyping results.
Discovery Follow-up Combined Annotation






(se) P-value N Location
Nearest
Gene






2.43E-02 7284 intronic SLC9A2






1.77E-04 7264 intronic SCN3A






7.61E-03 7278 39-UTR COL5A2






8.38E-05 7289 intergenic FLJ25363,
PVRL3-AS1






1.89E-05 7277 intronic ATP8A1






1.86E-05 7287 intergenic COX7C, MIR4280






2.67E-02 7268 intergenic MIR548A1, ID4






2.29E-02 7225 intronic BLK






2.81E-02 7277 intergenic MED30, EXT1








3.65E-47 7225 intronic ABO






9.14E-04 7253 intergenic CLMP, MIR4493






5.97E-02 7281 intergenic RASL11A, GTF3A
14 rs2274273 A/G 0.41 21.85E-01
(0.006)
2.35E-188 NA NA 21.85E-01
(0.006)
2.35E-188 3776 downstream DLGAP5








4.97e-465 7281 exonic LGALS3








1.50e-421 7292 exonic LGALS3






5.89E-04 7272 intergenic LOC283688,
ARNT2






9.52E-04 7257 intergenic DUS3L, NRTN






2.55E-02 7281 intergenic MAF, MIR548H4
Significant loci (P,561028, bold) and suggestive loci (P,561026) in the discovery phase that were taken forward for follow-up genotyping. In addition, 2 non-
synonymous variants (rs4644 and rs4652) were genotyped. AF: Allele Frequency; (se): standard error.
doi:10.1371/journal.pone.0047385.t002
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immunosorbent assay (BG Medicine, Inc., Waltham, USA). This
assay quantitatively measures the concentration of human
galectin-3 levels in EDTA plasma. This assay has high sensitivity
(lower limit of detection 1.13 ng/mL) and exhibits no cross
reactivity with collagens or other members of the galectin family
[26]. Commonly used medication like ACE-inhibitors, beta
blockers, spironolactone, furosemide, acetylsalicylic acid, warfarin,
coumarines, and digoxin have no interference with the assay [26].
All samples were assayed in duplicate. Two standard controls were
included in all runs: a lower control (expected value: 13.0–
23.1 ng/mL) and a higher control (expected value: 48.9–81.5 ng/
mL). The average lower control results were 16.6561.13
(coefficient of variance: 6.8%), and the average higher control
results were 68.1763.20 (coefficient of variance: 4.7%).
Genotyping, Quality control & Imputation
Genotyping in 4,016 of the total number of participants in
PREVEND was carried out using Illumina HumanCytoSNP-12
arrays. SNPs were called using Illumina Genome Studio software.
Forty-seven subjects were excluded from analyses because call rates
were ,0.95. Another 65 subjects were excluded because they were
closely related as judged based on Identity-By-Descent estimation
using PLINK v1.07. Population structure was assessed using PCA
based on 16,842 independent SNPs. Based on this analysis, an
additional 2 samples were excluded that diverged from the mean
with at least 3 standard deviations (Z-score.3) for the first 5 PCAs.
Another 35 subjects were excluded based on sex inconsistencies. We
excluded samples with a genetic similarity .0.1. Of 87 subjects no
phenotype was available because of missing plasma samples for
assessment of Galectin-3. As a consequence 3,776 (1,927 males,
1,849 females) were available for GWAS analysis. SNPs were
excluded with a minor allele frequency of,0.01, call rate,0.95, or
deviation from Hardy Weinberg equilibrium (P,161025). Ge-
nome wide genotype imputation was performed using Beagle v.
3.3.1 [27], 232,571 genotyped SNPs were imputed up to 2,269,099
autosomal SNPs with NCBI build 36 of Phase II HapMap CEU
data (release 22) as reference panel. Replication genotyping was
performed by KBiosciences (KBiosciences, Herts, UK) utilizing the
SNPline system in an additional 3,516 independent subjects of the
PREVEND study.
Gene-expression analyses
We investigated whether each of the associated variants had an
effect on gene expression levels by mapping cis-expression
quantitative trait loci (cis-eQTL) in 1,469 samples from peripheral
blood, for which gene expression level measurements were
obtained using Illumina HT12v3 and Illumina H8v2 platforms
[11]. Since the genotypes were imputed using the CEU population
of HapMap 2 release 24 as reference, eQTL effects were tested
using the imputation dosage values. Effects for SNPs (MAF .5%,
HWE .0.001) were considered cis-eQTLs when the distance
between the SNP and the midpoint position of the probe was
smaller than 1 MB. As multiple testing correction, we controlled
the false discovery rate (FDR) at 0.05, by comparing observed p-
values to the null distribution obtained from permuting the
expression phenotype labels relative to genotype labels 100 times.
We also determined the top eQTL SNP for each given probe and
tested whether the GWAS SNP had an independent effect on the
associated gene expression probe after removing the effect of the
top eQTL SNP.
Statistical analysis
Galectin-3 was non-normally distributed and was log trans-
formed before regression analyses. We calculated residuals of
galectin-3 levels after adjustment for age, age2, and gender.
GWAS analyses were performed on residuals using an additive
genetic model in PLINK (v 1.07) [28]. The most significant
(P,561028) SNPs (lead SNP) at each locus was taken forward for
further testing. The explained variance of the significant associ-
ations was analysed using the directly genotyped variants from the
replication stage. Fixed-effect meta-analysis was performed using
the variance weighting method of the METAL software package
to calculate the overall p-value. The Cox proportional-hazards
model was used to calculate the hazard ratio and 95% confidence
intervals (CI) of galectin-3. Based on our previous work, sequential
models were fitted without and with the SNP of interest [13]. The
first model including no covariates (unadjusted) and the second
model adjusted for age and gender and the third model adjusted
for: age, gender, previous myocardial infarction, previous stroke,
hypertension, hypercholesterolemia and diabetes. The assump-
tions underlying the proportional hazards model were tested and
found valid. Analyses were performed using STATA version 11.0
for Windows software (StataCorp LP, College Station, TX, USA).
Figure 4. Amino acid sequence (41 to 100) of Galectin-3. The
two antibodies used in the Galectin-3 assay recognize epitopes within
the N-terminus of the protein (white-colored amino acids). The capture
antibody of the galectin-3 assay binds to amino acids number 45 to 62
and the tracer antibody binds to amino acids number 70 to 100.
Indicated are the non-synonymous SNPs rs4644 and rs4652.
doi:10.1371/journal.pone.0047385.g004
Table 3. Relationship between identified SNPs with
expression of cis-genes in peripheral blood in 1,469 samples.
Chr SNP Position Gene Probe P-Value FDR
14 rs4644 54673724 LGALS3 5420377 2.4261027 0
14 rs4652 54674789 LGALS3 5420377 3.1061026 0
14 rs2274273 54673724 LGALS3 3450685 4.4561026 0
cis-genes: genes within 61 MB around the lead SNP. FDR: False discovery rate.
doi:10.1371/journal.pone.0047385.t003
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HR indicates hazard ratio per SD change in plasma galectin-3 level. * the multivariable model included age, sex, hypertension, hypercholesterolemia, diabetes, and
smoking.
doi:10.1371/journal.pone.0047385.t004
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